STOCK TITAN
  1. Home
  2. News
  3. RYZB

RayzeBio Inc - RYZB STOCK NEWS

Welcome to our dedicated page for RayzeBio news (Ticker: RYZB), a resource for investors and traders seeking the latest updates and insights on RayzeBio stock.

RayzeBio, Inc. (NASDAQ: RYZB) is a clinical-stage biopharmaceutical company pioneering targeted radiopharmaceutical therapeutics for cancer treatment. This news hub provides investors and medical professionals with timely updates on clinical developments, financial milestones, and strategic initiatives driving innovation in oncology therapeutics.

Access authoritative updates on RYZ101's Phase 3 trial progress, manufacturing expansions, and regulatory filings including the planned 2024 IND application for liver cancer therapy. Our curated news collection features verified press releases covering clinical data disclosures, partnership announcements, and financial performance updates following the company's successful 2023 IPO.

Stay informed about RayzeBio's vertically integrated operations and its pipeline of radiopharmaceutical candidates. This resource serves medical researchers tracking therapeutic advancements and investors analyzing the company's position in the evolving cancer treatment landscape. Bookmark this page for direct access to primary source materials and official corporate communications.

News

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Rhea-AI Summary
Bristol Myers Squibb (BMY) completes the acquisition of RayzeBio, Inc. (RYZB) to strengthen its oncology pipeline with radiopharmaceutical therapeutics. The acquisition includes RYZ101, a promising RPT targeting somatostatin receptor 2 in GEP-NETs and ES-SCLC. Bristol Myers Squibb plans to leverage RayzeBio's IND engine and manufacturing facility to accelerate preclinical and clinical programs, offering growth opportunities in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed the acquisition of RayzeBio, Inc. for approximately $4.1 billion, with 86% of RayzeBio's shares tendered. The transaction is expected to close on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Rhea-AI Summary
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announce the expiration of the waiting period under the HSR Act for BMY's tender offer to acquire RYZB for $62.50 per share in cash, totaling $4.1 billion. The transaction remains subject to the tender of a majority of RYZB's outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire RayzeBio (RYZB) for $4.1 Billion, Expanding Oncology Portfolio and Radiopharmaceutical Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) reported financial results for Q3 2023 and provided updates on clinical trials and corporate milestones. Recent highlights include RYZ101's Phase 3 clinical trial progress and a confirmed objective response rate of 29%. RYZ801 and RYZ811 IND filing for HCC is expected in 1H 2024. The company's manufacturing facility is on track for completion by the end of 2023, and it completed a $357 million IPO. The cash position as of September 30, 2023, was $540.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
earnings
-
News

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) will be participating in several investor conferences in November 2023 to discuss their innovative radiopharmaceutical pipeline for cancer treatment. The conferences include Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
News

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

Rhea-AI Summary
RayzeBio, Inc. has announced the appointment of Tim Van Hauwermeiren to its board of directors. Tim, the co-founder and CEO of argenx, brings extensive experience in general management and business development. RayzeBio aims to transform the oncology treatment landscape through targeted radiopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
management
-
News

FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

Rhea-AI Summary
RayzeBio's RYZ101 selected by FDA for CMC Development and Readiness Pilot program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
News

RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

Rhea-AI Summary
RayzeBio to present interim safety and efficacy data from Phase 1b trial at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
News

RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
RayzeBio, Inc. closes upsized $358 million IPO, selling 19,869,240 shares of common stock at $18.00 per share. Gross proceeds to RayzeBio were approximately $336.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
IPO offering
Stock RYZB logo
RayzeBio Inc

NYSE:RYZB

RYZB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RYZB Stock Data

3.75B
44.15M
9.69%
89.71%
1.41%
Biotechnology
Healthcare
Link
United States
San Diego